Brief: Candel Therapeutics Presents Phase 3 Clinical Trial Of Can-2409
29/09/2025 13:47
Sept 29 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS PRESENTS PHASE 3 CLINICAL TRIAL OF CAN-2409 IN LOCALIZED PROSTATE CANCER AT ASTRO 2025 Source text: ID:nGNX5Lvy86 Further company coverage: CADL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)